DEL POETA, GIOVANNI
 Distribuzione geografica
Continente #
NA - Nord America 71.424
AS - Asia 6.535
EU - Europa 6.492
SA - Sud America 985
AF - Africa 95
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 17
Totale 85.567
Nazione #
US - Stati Uniti d'America 71.226
SG - Singapore 2.922
DE - Germania 1.803
CN - Cina 1.497
UA - Ucraina 1.018
RU - Federazione Russa 935
BR - Brasile 798
IE - Irlanda 635
HK - Hong Kong 619
IT - Italia 613
VN - Vietnam 535
GB - Regno Unito 417
FR - Francia 300
FI - Finlandia 250
SE - Svezia 226
KR - Corea 219
BD - Bangladesh 189
JP - Giappone 183
CA - Canada 110
IN - India 87
NL - Olanda 72
AR - Argentina 52
PL - Polonia 52
MX - Messico 45
ZA - Sudafrica 43
AT - Austria 35
TR - Turchia 35
UZ - Uzbekistan 32
BE - Belgio 27
EC - Ecuador 27
ES - Italia 27
PH - Filippine 27
ID - Indonesia 24
IQ - Iraq 24
CL - Cile 20
SA - Arabia Saudita 20
VE - Venezuela 19
CO - Colombia 17
UY - Uruguay 17
PE - Perù 16
AU - Australia 15
PY - Paraguay 15
CZ - Repubblica Ceca 14
TH - Thailandia 14
PK - Pakistan 13
CH - Svizzera 9
EU - Europa 9
IL - Israele 9
JM - Giamaica 9
KE - Kenya 9
LT - Lituania 9
EG - Egitto 8
MA - Marocco 8
MY - Malesia 8
NP - Nepal 8
A2 - ???statistics.table.value.countryCode.A2??? 7
JO - Giordania 7
KZ - Kazakistan 7
RO - Romania 7
SN - Senegal 7
AL - Albania 6
DK - Danimarca 6
DM - Dominica 6
DO - Repubblica Dominicana 6
DZ - Algeria 6
GR - Grecia 6
LB - Libano 6
TN - Tunisia 6
AE - Emirati Arabi Uniti 5
AZ - Azerbaigian 5
IR - Iran 5
KG - Kirghizistan 5
CR - Costa Rica 4
HN - Honduras 4
HR - Croazia 4
NO - Norvegia 4
OM - Oman 4
PT - Portogallo 4
AO - Angola 3
BH - Bahrain 3
BO - Bolivia 3
BY - Bielorussia 3
GT - Guatemala 3
HU - Ungheria 3
LA - Repubblica Popolare Democratica del Laos 3
NZ - Nuova Zelanda 3
QA - Qatar 3
TW - Taiwan 3
AM - Armenia 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BW - Botswana 2
CY - Cipro 2
GD - Grenada 2
GE - Georgia 2
KW - Kuwait 2
MD - Moldavia 2
MN - Mongolia 2
PR - Porto Rico 2
PS - Palestinian Territory 2
Totale 85.551
Città #
Woodbridge 22.016
Wilmington 17.836
Houston 15.526
Fairfield 2.049
Ann Arbor 1.727
Singapore 1.658
Ashburn 1.340
Chandler 1.132
Jacksonville 920
Seattle 846
San Jose 787
Cambridge 712
Dublin 623
Hong Kong 603
Beijing 569
Dearborn 519
Medford 466
New York 317
Santa Clara 306
The Dalles 280
Dallas 245
Lawrence 219
Los Angeles 190
Ho Chi Minh City 181
Zhengzhou 173
Tokyo 143
Moscow 140
Buffalo 137
Lauterbourg 133
Hanoi 128
Rome 126
Mülheim 106
San Diego 104
Council Bluffs 78
Munich 76
São Paulo 76
Milan 64
Menlo Park 62
Chicago 56
University Park 49
London 48
Hefei 46
Boardman 43
Nanjing 42
Mountain View 41
Norwalk 40
Brooklyn 39
Montreal 39
Redondo Beach 39
Shanghai 38
Warsaw 38
Orem 37
Nuremberg 36
Helsinki 34
Creede 32
Frankfurt am Main 32
Phoenix 31
Toronto 31
Falls Church 29
Johannesburg 28
Palo Alto 28
Verona 27
Kunming 26
Redwood City 26
Guangzhou 25
Brussels 23
Denver 23
San Francisco 23
Chennai 22
Columbus 22
Haiphong 21
Rio de Janeiro 21
Atlanta 19
Da Nang 19
Detroit 19
Belo Horizonte 18
Poplar 17
Saint Petersburg 17
Wuhan 17
Amsterdam 16
Boston 16
Manchester 16
Mexico City 16
Montevideo 15
Nürnberg 15
Brasília 14
Lima 14
Stockholm 14
Ankara 13
North Bergen 13
Seoul 13
Turku 13
Bologna 12
Brno 12
Chengdu 12
Florence 12
Hangzhou 12
Biên Hòa 11
Hải Dương 11
Jakarta 11
Totale 74.155
Nome #
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia 632
Enumeration of CD34+ hematopoietic progenitor cells for clinical transplantation: comparison of three different methods 545
Femoral catheters: safety and efficacy in peripheral blood stem cell collection 541
A microgranular variant of acute promyelocytic leukemia with atypical morpho-cytochemical features and an early myeloid immunophenotype 533
CD7 expression in acute myeloid leukemia 529
A case of SRSF2 mutation in chronic lymphocytic leukemia 518
Enumeration of CD34+ hematopoietic progenitor cells for clinical transplantation: comparison of three different methods 517
AML-M0: A review of laboratory features and proposal of new diagnostic criteria 513
A novel t(11;12)(q23-24;q24) in a case of minimally-differentiated acute myeloid leukemia (AML-M0) 512
Collection of peripheral progenitor cells: a comparison between Amicus and Cobe-Spectra blood cell separators 510
Graft failure due to hemolytic uremic syndrome recurrence 499
Minimally differentiated acute myeloid leukemia (AML-MO): a distinct clinico-biologic entity with poor prognosis 498
Analysis of the expression of adhesion molecules on CD34+ progenitors from bone marrow, umbilical cord blood and G-CSF mobilized peripheral blood 498
Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian multicenter study 497
All-trans-retinoic acid plus low-doses of cytarabine for the treatment of poor-risk acute myeloid leukemias 495
A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes 494
Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors 491
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 490
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments 488
High expression levels of vla-4 (CD49d) on mobilised peripheral blood stem cells are associated with rapid engraftment in multiple myeloma patients receiving autologous transplant 487
Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML) 482
Clinical significance of CD38 expression in chronic lymphocytic leukemia 479
Comparison between conventional banding analysis and FISH screening with an AML specific set of probes in 260 patients 475
Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. 473
Acute lymphoblastic leukemia subsequent to autoimmune hemolytic anemia: a case report 473
The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. 471
Biological profile of 23 cases of minimally differentiated acute myeloid leukemia (AML-MO) and its clinical implications 471
Multiparametric analysis for the enumeration of CD34+ cells from bone marrow and stimulated peripheral blood 471
Leukocyte alkaline-phosphatase score in plasma-cell dyscrasias - correlation with disease severity and circulating levels of granulocyte-colony-stimulating factor 470
Central Nervous System Involvement in Adult Acute Lymphoblastic Leukemia: Diagnostic Tools, Prophylaxis, and Therapy. 470
Diagnosis of acute myeloid leukemia and system Coulter VCS 469
Surface-antigen expression profiling (SEP) in B-cell chronic lymphocytic leukemia (B-CLL): Identification of markers with prognostic relevance 468
Intensive treatment of patients age 60 years and older with de novo acute myeloid leukemia - Analysis of prognostic factors 468
Femoral catheters: safety and efficacy in peripheral blood stem cell collection 465
Efficacy and safety of human leucocyte interferon-alpha treatment in patients younger than 60 years of age with polycythaemia vera 464
P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia 463
All-trans retinoic acid (ATRA) administration during pregnancy in relapsed acute promyelocytic leukemia 463
Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia 463
Clinical implications of cytokine and soluble receptor measurements in patients with newly-diagnosed aggressive non-Hodgkin's lymphoma 462
Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia 462
Minimally differentiated acute myeloid leukemia (AML-MO): Comparison of 25 cases with other French-American-British subtypes 461
Biological features of acute myeloid leukemia in the elderly 460
Bone marrow necrosis as a terminal complication of a very long-lasting polycythemia vera 459
Clinical relevance of minimal residual disease detection in adult acute myeloid leukemia 459
Response to B-cell-depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura 456
Analysis of regulatory T cell changes in patients with idiopathic thrombocytopenic purpura receiving B-cell depleting therapy with rituximab 455
Soluble factors levels in the initial staging of high-grade non-Hodgkin's lymphomas 455
In vitro down-regulation of bcl-2 expression by all-trans retinoic acid in AML blasts 454
P-glycoprotein and BCL-2 levels predict outcome in adult acute lymphoblastic leukaemia 451
In vitro infection of leukemic bone marrow with HTLV-I generates immortalized cell lines expressing T or myeloid cell phenotype 450
Monocytes/macrophages but not T lymphocytes are the major targets of the CCL3/CCL4 chemokines produced by CD38(+)CD49d(+) chronic lymphocytic leukaemia cells 447
Activation-induced cytidine deaminase and CD38 expression in B-cell chronic lymphocytic leukemia 446
Chromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene translocation: results in 378 adult patients 445
Lecam1/Icam1 ratio identifies a distinct pattern on normal and myelodysplastic bone marrow CD34+ progenitors cells 445
AML-M0: a biological and clinical profile 445
Chronic lymphocytic leukemia-associated immune thrombocytopenia treated with rituximab: a retrospective study of 21 patients 443
FISH analysis for CML monitoring? 443
Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. 443
Graft failure due to hemolytic uremic syndrome recurrence 442
Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia 442
Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab 441
CD7 Expression in acute myeloid leukemia 441
Biological pattern of AML-M0 versus AML-M1: Response 441
Complete regression of cutaneous lesions of refractory Ph+ ALL after 4 weeks of treatment with BMS-354825 439
A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia 439
Pure erythroid leukemia in advanced breast cancer. 438
Molecular characterization of Ph' + hybrid acute leukemia 438
NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: Evidence for a NOTCH1 mutation-driven epigenetic dysregulation 438
The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience 437
Gelatinous degeneration of the bone marrow: two case reports showing different hematological features and clinical outcomes 437
Management of hematological malignancies in patients affected by renal failure 436
Hodgkin disease subsequent to follicular lymphoma on maintenance rituximab 436
Cutaneous involvement in multiple myeloma and bortezomib 435
Mitoxantrone in combination with etoposide and cytarabine for treatment of poor prognosis acute non lymphoid leukemia patients 435
Clinical implication of cytokine and soluble receptor measurements in patients with newly diagnosed aggressive non Hodgkin Lymphomas 434
Minimally differentiated acute myeloid-leukemia (aml-mo): cytochemical, immunophenotypic and cytogenetic analysis of 19 cases 433
Multidimensional flow cytometry for detection of minimal residual disease in acute myeloid leukemia 432
Contribution of immunophenotypic and genotypic analysis to the diagnosis of acute leukemia 432
Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia 431
Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia 429
Discriminant function analysis as decision support system for the diagnosis of acute leukemia with a minimal four color screening panel and multiparameter flow cytometry immunophenotyping 428
How would I manage a sample submitted for flow cytometry analysis for suspicious chronic lymphocytic leukaemia 426
Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-M0) 426
Red blood cell depletion and cryopreservation of umbilical cord blood (UCB) 425
IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia. 425
A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia 422
All-trans retinoic acid and low dose cytosine arabinoside for the treatment of "poor prognosis" acute myeloid leukemia 422
Clinical heterogeneity of idiopathic CD4+T lymphocytopenia 421
Role of human leukocyte interferon-alpha in the treatment of patients with polycythemia vera 421
Cytogenetic and molecular diagnostic characterization combined to post-consolidation minimal residual disease assessment by flow-cytometry improves risk stratification in adult acute myeloid leukemia 420
ZAP-70 expression in B-cell chronic lymphocytic leukemia: evaluation by external (isotypic) or internal (T/NK cells) controls and correlation with IgV(H) mutations 420
Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. 418
Fluorescence in situ hybridization and conventional cytogenetics for the diagnosis of 11q23(+)/MLL+ translocation in leukaemia 418
Potential therapeutic role of antagomiR17 for the treatment of chronic lymphocytic leukemia. 418
Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation 417
CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival 417
Analysis of IgV gene mutations in B cell chronic lymphocytic leukaemia according to antigen-driven selection identifies subgroups with different prognosis and usage of the canonical somatic hypermutation machinery 417
High interleukin-6 plasma levels in acute promyelocytic leukemia 417
Dismal Outcome of Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia after Azacitidine Failure in a Daily-Life Setting. 417
Minimally differentiated acute myeloid leukemia (AML-MO): A distinct clinico-biologic entity with poor prognosis 416
Totale 45.803
Categoria #
all - tutte 186.805
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 186.805


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021101 0 0 0 0 0 0 0 0 0 0 0 101
2021/20222.169 71 282 61 107 39 206 119 112 115 222 138 697
2022/20232.879 362 240 206 281 194 631 269 165 286 10 182 53
2023/2024875 101 35 39 15 101 297 44 29 19 11 14 170
2024/20254.519 152 1.210 582 250 61 187 400 207 411 349 314 396
2025/20267.666 680 350 1.094 630 605 305 862 944 892 692 339 273
Totale 85.985